![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMOD3 |
Gene summary for TMOD3 |
![]() |
Gene information | Species | Human | Gene symbol | TMOD3 | Gene ID | 29766 |
Gene name | tropomodulin 3 | |
Gene Alias | UTMOD | |
Cytomap | 15q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q9NYL9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
29766 | TMOD3 | LZE2T | Human | Esophagus | ESCC | 7.95e-04 | 8.34e-01 | 0.082 |
29766 | TMOD3 | LZE4T | Human | Esophagus | ESCC | 1.91e-19 | 8.00e-01 | 0.0811 |
29766 | TMOD3 | LZE5T | Human | Esophagus | ESCC | 4.05e-04 | 9.78e-01 | 0.0514 |
29766 | TMOD3 | LZE7T | Human | Esophagus | ESCC | 1.49e-07 | 5.87e-01 | 0.0667 |
29766 | TMOD3 | LZE8T | Human | Esophagus | ESCC | 3.05e-12 | 5.22e-01 | 0.067 |
29766 | TMOD3 | LZE20T | Human | Esophagus | ESCC | 5.99e-09 | 3.77e-01 | 0.0662 |
29766 | TMOD3 | LZE22D1 | Human | Esophagus | HGIN | 3.30e-03 | 2.42e-01 | 0.0595 |
29766 | TMOD3 | LZE22T | Human | Esophagus | ESCC | 6.36e-05 | 4.53e-01 | 0.068 |
29766 | TMOD3 | LZE24T | Human | Esophagus | ESCC | 3.21e-20 | 5.56e-01 | 0.0596 |
29766 | TMOD3 | LZE21T | Human | Esophagus | ESCC | 3.23e-05 | 5.43e-01 | 0.0655 |
29766 | TMOD3 | LZE6T | Human | Esophagus | ESCC | 3.67e-09 | 7.54e-01 | 0.0845 |
29766 | TMOD3 | P1T-E | Human | Esophagus | ESCC | 5.09e-18 | 1.10e+00 | 0.0875 |
29766 | TMOD3 | P2T-E | Human | Esophagus | ESCC | 6.80e-28 | 4.10e-01 | 0.1177 |
29766 | TMOD3 | P4T-E | Human | Esophagus | ESCC | 5.40e-37 | 1.02e+00 | 0.1323 |
29766 | TMOD3 | P5T-E | Human | Esophagus | ESCC | 1.58e-44 | 8.31e-01 | 0.1327 |
29766 | TMOD3 | P8T-E | Human | Esophagus | ESCC | 8.45e-60 | 1.34e+00 | 0.0889 |
29766 | TMOD3 | P9T-E | Human | Esophagus | ESCC | 3.95e-28 | 8.37e-01 | 0.1131 |
29766 | TMOD3 | P10T-E | Human | Esophagus | ESCC | 6.83e-58 | 1.04e+00 | 0.116 |
29766 | TMOD3 | P11T-E | Human | Esophagus | ESCC | 1.56e-09 | 5.68e-01 | 0.1426 |
29766 | TMOD3 | P12T-E | Human | Esophagus | ESCC | 9.31e-34 | 7.48e-01 | 0.1122 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003021820 | Oral cavity | OSCC | erythrocyte differentiation | 74/7305 | 120/18723 | 4.09e-07 | 6.06e-06 | 74 |
GO:000806417 | Oral cavity | OSCC | regulation of actin polymerization or depolymerization | 104/7305 | 188/18723 | 3.99e-06 | 4.66e-05 | 104 |
GO:00900688 | Oral cavity | OSCC | positive regulation of cell cycle process | 126/7305 | 236/18723 | 4.75e-06 | 5.44e-05 | 126 |
GO:003083216 | Oral cavity | OSCC | regulation of actin filament length | 104/7305 | 189/18723 | 5.48e-06 | 6.14e-05 | 104 |
GO:003083318 | Oral cavity | OSCC | regulation of actin filament polymerization | 96/7305 | 172/18723 | 5.56e-06 | 6.20e-05 | 96 |
GO:000815418 | Oral cavity | OSCC | actin polymerization or depolymerization | 117/7305 | 218/18723 | 7.38e-06 | 8.04e-05 | 117 |
GO:003004118 | Oral cavity | OSCC | actin filament polymerization | 103/7305 | 191/18723 | 1.94e-05 | 1.87e-04 | 103 |
GO:19019924 | Oral cavity | OSCC | positive regulation of mitotic cell cycle phase transition | 56/7305 | 93/18723 | 2.76e-05 | 2.56e-04 | 56 |
GO:003133318 | Oral cavity | OSCC | negative regulation of protein-containing complex assembly | 79/7305 | 141/18723 | 3.01e-05 | 2.76e-04 | 79 |
GO:19019895 | Oral cavity | OSCC | positive regulation of cell cycle phase transition | 65/7305 | 115/18723 | 1.03e-04 | 7.69e-04 | 65 |
GO:00432445 | Oral cavity | OSCC | regulation of protein-containing complex disassembly | 65/7305 | 121/18723 | 7.08e-04 | 3.90e-03 | 65 |
GO:00426927 | Oral cavity | OSCC | muscle cell differentiation | 175/7305 | 384/18723 | 4.79e-03 | 1.92e-02 | 175 |
GO:00436244 | Oral cavity | OSCC | cellular protein complex disassembly | 68/7305 | 136/18723 | 5.84e-03 | 2.24e-02 | 68 |
GO:190290417 | Oral cavity | OSCC | negative regulation of supramolecular fiber organization | 81/7305 | 167/18723 | 7.70e-03 | 2.82e-02 | 81 |
GO:00615153 | Oral cavity | OSCC | myeloid cell development | 38/7305 | 71/18723 | 9.12e-03 | 3.27e-02 | 38 |
GO:003103217 | Oral cavity | OSCC | actomyosin structure organization | 93/7305 | 196/18723 | 9.63e-03 | 3.41e-02 | 93 |
GO:004325426 | Oral cavity | EOLP | regulation of protein-containing complex assembly | 112/2218 | 428/18723 | 1.58e-16 | 1.35e-13 | 112 |
GO:190290326 | Oral cavity | EOLP | regulation of supramolecular fiber organization | 93/2218 | 383/18723 | 6.50e-12 | 1.08e-09 | 93 |
GO:000701526 | Oral cavity | EOLP | actin filament organization | 102/2218 | 442/18723 | 1.61e-11 | 2.48e-09 | 102 |
GO:003009926 | Oral cavity | EOLP | myeloid cell differentiation | 91/2218 | 381/18723 | 2.87e-11 | 4.15e-09 | 91 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMOD3 | SNV | Missense_Mutation | c.473N>A | p.Gly158Asp | p.G158D | Q9NYL9 | protein_coding | tolerated(0.64) | benign(0.007) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
TMOD3 | SNV | Missense_Mutation | novel | c.871G>T | p.Asp291Tyr | p.D291Y | Q9NYL9 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
TMOD3 | SNV | Missense_Mutation | novel | c.959N>T | p.Tyr320Phe | p.Y320F | Q9NYL9 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TMOD3 | SNV | Missense_Mutation | rs757302528 | c.526N>A | p.Val176Ile | p.V176I | Q9NYL9 | protein_coding | tolerated(0.24) | benign(0.012) | TCGA-CI-6622-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
TMOD3 | deletion | Frame_Shift_Del | rs759399045 | c.275delN | p.Ile97TyrfsTer23 | p.I97Yfs*23 | Q9NYL9 | protein_coding | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | ||
TMOD3 | SNV | Missense_Mutation | rs746856695 | c.833N>T | p.Ala278Val | p.A278V | Q9NYL9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMOD3 | SNV | Missense_Mutation | novel | c.343N>A | p.Leu115Ile | p.L115I | Q9NYL9 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMOD3 | SNV | Missense_Mutation | c.43C>A | p.Leu15Ile | p.L15I | Q9NYL9 | protein_coding | tolerated(1) | benign(0.107) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMOD3 | SNV | Missense_Mutation | c.311N>A | p.Pro104His | p.P104H | Q9NYL9 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMOD3 | SNV | Missense_Mutation | c.73T>C | p.Ser25Pro | p.S25P | Q9NYL9 | protein_coding | tolerated(0.05) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |